Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stephen Tirrell
Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies
Investigational New Drugs
Oncology
Pharmacology
Related publications
A Phase I Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14c]-Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I Study of GSK461364, a Specific and Competitive Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
Hematologic Malignancies
Oncologist
Cancer Research
Medicine
Oncology
Ih2 Inhibition Enhances Proteasome Inhibitor Responsiveness in Hematological Malignancies
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies
Cancer
Cancer Research
Oncology
A Phase I Study of Indoximod in Patients With Advanced Malignancies
Oncotarget
Oncology
